Durga Borkar, MD
Ophthalmology · Philadelphia, PANPI 1063851160
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (48.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Astellas Pharma US Inc at 55.2% of the total. Reporting peaked in 2024 at $83,579 and has fallen 64.3% since, to $29,827 in 2025. Among ophthalmology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 163 payments — averaging $918.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$83K
- Genentech USA, Inc.$14K
- AbbVie$12K
- F. Hoffmann-la Roche AG$9K
- Apellis Pharmaceuticals, Inc.$9K
- Ocular Therapeutix, Inc.$6K
- plus $18K from 14 others
Across 66 payments — averaging $841.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$49K
- Regeneron$6K
What the payments were for
- Consulting fees$73,00849%
- Speaking & faculty fees$60,31240%
- Travel & lodging$9,2626%
- Food & beverage$7,0905%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 55 | $82,628 |
| Genentech USA, Inc. | 13 | $14,152 |
| AbbVie | 22 | $12,228 |
| F. Hoffmann-la Roche AG | 6 | $8,728 |
| Apellis Pharmaceuticals, Inc. | 7 | $8,598 |
| Ocular Therapeutix, Inc. | 8 | $5,566 |
| Regeneron | 9 | $5,458 |
| Astellas Pharma Global Development | 2 | $5,004 |
| Eyepoint US, Inc. | 16 | $4,115 |
| Glaukos Corporation | 2 | $1,286 |
| Genentech, Inc. | 11 | $551 |
| Bausch & Lomb Americas Inc. | 3 | $234 |
| Regeneron Healthcare Solutions, Inc. | 2 | $213 |
| Heidelberg Engineering, Inc. | 1 | $205 |
| Dutch Ophthalmic, USA | 1 | $150 |
| Carl Zeiss Meditec, Inc. | 1 | $142 |
| Alcon | 1 | $136 |
| Harrow Eye, LLC | 1 | $115 |
| Biogen | 1 | $84 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $80 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Izervay$87,110
- VABYSMO$9,520
- OZURDEX$7,725
- Syfovre$6,937
- EYLEA HD$4,498
- Lucentis$4,438
- EYP-1901$3,633
- DEXTENZA$443
- EYLEA$356
- YUTIQ$238
- Spectralis$205
- EVA, combined machine$150
- TISSUEBLUE$150
- ARTEVO 800$142
- Constellation$136
- DURYSTA$125
- ALPHAGAN P$122
- LUMIGAN$119
- IHEEZO$115
- XIPERE$110
How this compares
$149,673 in reported general payments places this provider in the 95th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Difluprednate | 13 | $1,889 |
| Prednisolone Acetate | 51 | $1,749 |
| Ketorolac Tromethamine | 48 | $782 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 47 | $749 |
| Latanoprost | 13 | $108 |
| Brimonidine Tartrate | 21 | $94 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Philadelphia
- Julia HallerPhiladelphia$1.5M
- Beeran MeghparaPhiladelphia$496K
- Jonathan MyersPhiladelphia$359K
- Mark BlecherPhiladelphia$357K
- Anton KolomeyerPhiladelphia$355K
- Rachel NiknamPhiladelphia$142K
- Joseph MarkoffPhiladelphia$130K
- Leslie KatzPhiladelphia$105K
- Zeba SyedPhiladelphia$99K
- Cesar BricenoPhiladelphia$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.